The Most Promising Metastatic Breast Cancer Trials

One of the most challenging scenarios in the medical field today is the battle against metastatic breast cancer. This article focuses on five of the most promising metastatic breast cancer trials currently enrolling.

Epidemiology, Diagnosis, and Treatment of Metastatic Breast Cancer

Metastatic breast cancer is a stage of cancer in which the tumor has spread beyond the initial site in the breast to other parts of the body. Globally, breast cancer is the most common cancer among females, and metastatic breast cancer accounts for a reported 6-10% of all new breast cancer diagnoses, susceptible to significantly reduce the survival rates.

Diagnosing metastatic breast cancer typically involves a physical examination, detailing the patient’s medical history and often coupled with further tests such as blood tests, biopsy, or scans to identify the spread. Traditionally, treatments include surgery, radiation therapy, hormone therapy, chemotherapy, or targeted therapy. However, the extensive behavior variations of metastatic breast cancer demand more effective treatment strategies. For this reason, several clinical trials have been initiated to discover new medication approaches.

Most Promising Metastatic Breast Cancer Trials Currently Open for Enrollment

1. Trastuzumab Deruxtecan (NCT03523585)

First on the list is Trastuzumab Deruxtecan known also by its NCT number, NCT03523585. This is a global randomized Phase III study of Trastuzumab Deruxtecan versus T-DM1 in patients who had HER2-positive metastatic breast cancer. The objective is to evaluate its effect on progression-free survival.

2. Margetuximab plus Pembrolizumab (NCT04082455)

Margetuximab plus Pembrolizumab is commonly known as the NCT04082455 trial. It is an open-label treatment trial involving patients with advanced HER2-positive breast cancer who have previously received anti-HER2-targeted therapy.

3. Atezolizumab and Paclitaxel (NCT03498716)

Third in our list, the clinical trial NCT03498716 is investigating whether combining Atezolizumab and Paclitaxel could enhance progression-free survival and overall survival rates among TNBC patients.

4. Alpelisib (BYL719) (NCT04403924)

Next, we have the Alpelisib trial (NCT04403924). It is a Phase III trial that investigates how the targeted therapy BYL719 works in HR+/HER2- advanced breast cancer with PIK3CA mutation, following cyclin-dependent kinase 4/6 inhibitor therapy.

5. Palbociclib (NCT02774681)

The NCT02774681 trial - coined as a trial studying Palbociclib, aims to establish a connection between the drug and improved overall survival in patients with molecular apocrine HER2-Negative metastatic breast cancer.

Conclusively, the most promising metastatic breast cancer trials offer a glimmer of hope for patients fighting this battle. By delving into more advanced treatment strategies, these trials contribute to the progressive steps towards counteracting metastatic breast cancer.